Objectives. To evaluate differences in baseline characteristics between etanercept-and adalimumabtreated JIA patients and to reveal factors that influence the choice between these TNF inhibitors, which are considered equally effective in the recent ACR recommendations for JIA treatment.
Introduction
JIA patients refractory to MTX treatment (dosed 515 mg/m 2 /wk) are eligible for treatment with biologics.
In 1999, etanercept, an anti-TNF-a receptor fusion protein, was the first biologic to be approved by the U.S. Food and Drug Administration for the treatment of JIA (in 2000 the European Medicines Evaluating Agency followed). Its efficacy and safety have been demonstrated in a randomized controlled withdrawal trial and several longterm observational studies, including the Dutch Arthritis and Biologicals in Children (ABC) register [13] . In 2008, a second biologic agent, adalimumab, a monoclonal anti-TNF antibody, was approved for polyarticular JIA after its efficacy was established in a placebo-controlled withdrawal trial [4] . Adalimumab is considered to be the preferred biologic in treating uveitis, a condition strongly associated with JIA [59] . Observational data on the use of adalimumab for JIA are limited [10, 11] . The ACR recommendations for JIA consider these anti-TNF agents equally [12] . In RA, adalimumab is considered as effective as etanercept [13] . Neither JIA nor adult RA head-to-head trials exist that compare etanercept and adalimumab. When deciding between these biologics, physicians can only rely on limited evidence and have to consider other factors.
Qualitative research can provide insight into how and why physicians make decisions when prescribing medication, which cannot be deduced from quantitative studies [14] .
We compared baseline characteristics of biologic-naïve patients initiating adalimumab or etanercept included in the Dutch ABC register to observe the real-life prescription patterns. Additionally we performed focus group interviews with paediatric rheumatologists and rheumatologists to evaluate the factors that determined their treatment choice.
Patients and methods

Patient population and baseline data
This study is part of the ABC register-a national ongoing multicentre study that aims to include all Dutch patients with JIA treated with biologics. The ABC register contains prospectively obtained data since the introduction of etanercept for JIA in 1999. The register was approved by the Medical Ethics Committee at Erasmus Medical Center and all participating hospitals. Subjects' written consent was obtained according to the Declaration of Helsinki. At baseline, data on demographics and disease characteristics were collected as well as variables of the JIA disease activity core set [15] . At baseline, 9.9% of the variables were missing, with a median of zero missing variables per patient [interquartile range (IQR) 01].
For this analysis, we included biologic-naïve patients who initiated etanercept or adalimumab between March 2008 (when adalimumab became available) and December 2011. JIA patients without active arthritis initiating biologics to treat uveitis only were not included in the analyses (as this would have biased the results), nor were patients participating in treatment strategy trials.
Focus group methods
The qualitative part consisted of two focus group interviews, carried out in autumn 2011. Twenty paediatric rheumatologists and rheumatologists involved in the care of paediatric patients, all members of the Dutch Society for Paediatric Rheumatology prescribing biologic treatment, were recruited by e-mail. Forty percent participated. The first focus group comprised two rheumatologists and three paediatric rheumatologists, and the second comprised three paediatric rheumatologists. The participants worked in six different areas in seven different hospitals.
The first interview lasted 1 h and the second 37 min. Two researchers were present, the moderator (S.G.) and a research physician (J.A.). The interview guide comprised questions on perceived effectiveness, motivation for initiation, experience with the different therapies and possible contraindications. In addition, participants were confronted with data retrieved from the ABC register comparing baseline characteristics of the two patient groups and asked for their interpretation.
J.A. audio-recorded and transcribed the focus group interviews verbatim. Transcripts were checked for accuracy and sent to participants for checking.
Data analysis
Descriptive statistics were presented as absolute frequencies or median values with IQR. Differences in patient and disease characteristics at baseline were compared using Fisher's exact test or MannWhitney U test whenever applicable. Differences were considered significant at a twosided P-value <0.05. Data were analysed using the SPSS for Windows package, version 17.0.2 (SPSS Inc., Chicago, IL, USA).
For transcript analysis, a phenomenological approach was used [16] . Transcripts were read and reread to get a global impression and subsequently coded following an open coding strategy by J.A. S.G. checked the coding; J.A. and S.G. discussed coding until consensus was reached. Subsequently key units were identified from the codes and summarized in broader themes. A theme was considered more important according to the frequency of occurrence during the interviews. MAXQDA 10 software was used for analysis of qualitative data.
Results
Data from the ABC register
Patient and disease characteristics are presented in Table 1 . A total of 193 previously biologic-naïve JIA patients initiated etanercept and 21 initiated adalimumab. Patients treated with adalimumab had longer disease duration and were more often diagnosed with persistent oligoarticular JIA. Most adalimumab-treated patients (71%) had a history of uveitis. Six patients did not have a history of uveitis and presented with extended oligoarticular (one), PsA (one) and enthesitis-related arthritis (ERA) (four) JIA categories. Etanercept-treated patients had higher disease activity indicated by higher Childhood www.rheumatology.oxfordjournals.org Health Assessment Questionnaire (CHAQ) scores and more joints with active arthritis.
Focus group results
The main factors influencing decision making are presented in Table 2 . These factors can be summarized in three broad categories: internal factors (related to the drug, the patients characteristics or the doctor), external factors (related to brand awareness, governmental regulations and drug availability) and costs.
Pain on injection was the most important drug-related factor mentioned. All physicians agreed that paediatric patients experience the injections of adalimumab as painful.
The prefilled formulation of etanercept is also perceived to be irritating; its self-dissoluble formula was therefore preferred by most. The availability of a formulation specifically adapted for paediatric use was seen as an advantage of etanercept. Although adalimumab has recently improved its paediatric formulation, it was thought to be less practical, as it still contains the adult dose.
The subject of costs featured less prominently in the discussion than other factors. Costs were considered especially important when dosages other than the adult dosage were prescribed. In adult dosage, etanercept and adalimumab are equally expensive [17] . Government regulations with regard to reimbursement were mentioned in relation to costs; if these change, costs could become more important. Adalimumab was preferred by all physicians when a history of uveitis or active uveitis was present: 'In recent years it has been shown that etanercept might be less effective for uveitis . . . resulting in the fact that when I am considering prescribing anti-TNF to a child who has or has had uveitis I would choose adalimumab in the first place'. Two physicians considered it for all patients with a higher risk of developing uveitis.
Treatment with adalimumab was considered in patients with complaints suggestive of IBD, but in whom IBD could not be confirmed. ' We also have-I know, this is absolutely not evidence based-children with nonspecific intestinal complaints. They have been seen by gastro-enterologists, they have had endoscopies, everything, and then, suddenly out of the blue, they are diagnosed with JIA. In that group I am sometimes a little more inclined to prescribe adalimumab'. Other indications mentioned for prescribing adalimumab rather than etanercept were ERA and PsA.
A doctor-related factor that received a lot of attention was experience. For three physicians, gaining experience with a new treatment was a reason to prescribe adalimumab. However, most physicians strongly indicated etanercept to be their first choice, relying heavily on available efficacy data, their personal familiarity with the drug and the favourable safety profile without immunogenicity. The rheumatologists also treating adult RA patients had more extensive experience with adalimumab and were therefore less reluctant to prescribe it to children, as illustrated by this quote: 'we obviously have this long-lasting experience with adalimumab, for me at least [lack of experience] is not a reason not to start treatment with adalimumab in a child'.
Finally, practising evidence-based medicine featured prominently in the discussions. During the interviews physicians were constantly referring to literature and evidently trying to base their decisions on the latest available data.
No pressure from the industry was noted, apart from a few comments on advertisements received from and questions asked by visiting representatives of pharmaceutical companies. However, three physicians did suggest that marketing and brand awareness played a role: 'to be honest, you do hear the name adalimumab more and more, as a result of which I think: this might be a suitable treatment for this specific patient'.
Discussion
This study shows that for JIA both etanercept and adalimumab are being prescribed. Focus group interviews identified a preference for etanercept. This was reflected in the absolute numbers, as 90% of the biologic-naïve patients were started on etanercept. Adalimumab-treated patients were characterized by a history of uveitis, longer disease duration and lower disease activity. The presence of uveitis was acknowledged by interviewees to be one of the most important factors that directed their choice towards adalimumab. Painful adalimumab injections and more extensive personal and scientific experience with etanercept were the most important reasons to be reticent with prescription of adalimumab.
The observation that JIA-associated uveitis is a reason to consider treatment with biologics is consistent with the literature. In contrast to its proven efficacy in JIA, results for etanercept in the treatment of refractory uveitis are less satisfactory and adalimumab is now preferred for uveitis [57, 9, 18, 19] . Uveitis develops most often in the oligoarticular categories, which formed the largest part of the adalimumab-treated group. These categories are generally controlled for longer by treatment modalities other than TNF blockers, which may account for the longer disease duration in the adalimumab-treated group. The presence of uveitis may also explain why disease activity scores (related to arthritis) were lower in patients treated with adalimumab.
ERA and PsA were overrepresented in the adalimumabtreated group. This is in line with indications to consider adalimumab mentioned during the focus group interviews. Spondylarthritides are associated with psoriasis and IBD, and TNF-a also plays a role in the pathogenesis of psoriasis and IBD. TNF inhibitors seem equally effective for joint symptoms and skin symptoms, but on gut www.rheumatology.oxfordjournals.org manifestations monoclonal antibodies against TNF-a seem to be more effective [20, 21] .
The present study indicates that the process of prescribing new drugs and implementing them in daily care is complex and takes time, a finding also recognized in other qualitative studies investigating prescription patterns [2226] . Although the ACR recommendations do not differentiate between the two TNF inhibitors, the adaptation of the prescription pattern apparently involves many factors in addition to the effectiveness of the drug for JIA. These factors were put together in three categories: internal factors, external factors and costs [23] . Experience with the drug was considered a major factor. Etanercept has had a head start concerning safety, with over 10 years of safety data compared with only 4 years for adalimumab.
Costs of TNF inhibitors are approximately the same when prescribed in adult dosages and might therefore play a less important role, especially in older children. Cost is apparently a secondary factor that comes into play when more experience is acquired with the new drug, and this could change when reimbursement regulations change. It could also be that moral resistance is felt against cost-conscious statements, and therefore they are less often mentioned in focus group interviews. Although a notion of cost-effectiveness has to be present, often doctors feel the emphasis should be on patientcentred factors. The fact that brand awareness and pressure from pharmaceutical companies were mentioned infrequently may be related to this same idea, and their influence might therefore be underestimated.
This study is limited in its size. Because only a few patients received adalimumab, these data should be interpreted with caution.
Not all rheumatologists and paediatric rheumatologists invited for focus group interviews were able to participate. Therefore the influential factors identified might not be representative for all Dutch physicians treating JIA patients with biologics. Nevertheless, physicians originated from different regions, covering the whole of the Netherlands. In both interviews, the same considerations were mentioned and we feel no topics were left out.
The researcher who moderated the interview was experienced in qualitative research. She was a rheumatologist herself, which brings a risk of peer review. However, this possible problem was recognized beforehand and she focused on her role as moderator.
In conclusion, both etanercept and adalimumab are prescribed for JIA. Even though both TNF inhibitors are considered equally effective, paediatric rheumatologists still prefer etanercept. Patient characteristics differed between the two treatment groups, the most important being the presence or risk of uveitis in the adalimumab-treated group. In deciding which biologic to prescribe to the biologic-naïve patient, paediatric rheumatologists take into account drug and patient factors to tailor prescriptions. They consider newly published data and cautiously implement this into daily care. Existing experience with an already established drug, in this case etanercept, makes it more difficult to shift preferences. Drug marketing and costs seem to play a minimal role in this process.
Rheumatology key messages
. Drug-and patient-related factors are considered to individualize prescriptions of anti-TNF treatment in JIA. . Dutch paediatric rheumatologists prefer etanercept over adalimumab in JIA because of their existing experience. . Adalimumab is mainly prescribed to JIA patients with concurrent or a risk of uveitis.
